PDCD1 and small cell lung carcinoma: Given that LS-SCLC is a condition characterized by substantial unmet clinical needs, the utilization of a combination of anti-TIGIT antibody and anti-PD-1/L1 antibody could potentially amplify the immunotherapeutic effect while maintaining a tolerable safety profile.